An analysis of research biopsy core variability from over 5000 prospectively collected core samples

Author:

Bhamidipati Deepak,Verma Anuj,Sui Dawen,Maru Dipen,Mathew Grace,Lang Wenhua,Posadas Juan,Hein Joshua,Kopetz Scott,Futreal Andrew,Wistuba Ignacio I.,Gupta Sanjay,Lee J. JackORCID,Overman Michael J.,Tam Alda L.

Abstract

AbstractFactors correlated with biopsy tissue adequacy and the prevalence of within-biopsy variability were evaluated. Totally, 1149 research biopsies were performed on 686 patients from which 5090 cores were assessed. Biopsy cores were reviewed for malignant percentage (estimated percentage of cells in the core that were malignant) and malignant area (estimated area occupied by malignant cells). Linear mixed models and generalized linear mixed models were used for the analysis. A total of 641 (55.8%) biopsies contained a core with <10% malignant percentage (inadequate core). The chance of an inadequate core was not influenced by core order, though the malignant area decreased with each consecutive core (p < 0.001). Younger age, bone biopsy location, appendiceal tumor pathology, and responding/stable disease prior to biopsy increased the odds of a biopsy containing zero adequate cores. Within-biopsy variability in core adequacy is prevalent and suggests the need for histological tumor quality assessment of each core in order to optimize translational analyses.

Funder

The University of Texas MD Anderson Cancer Center Moon Shots Program™

Publisher

Springer Science and Business Media LLC

Subject

Computer Science Applications,History,Education

Reference39 articles.

1. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 8.2020). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf (2020).

2. National Comprehensive Cancer Network. Breast Cancer (Version 6.2020). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (2020).

3. National Comprehensive Cancer Network. Colon Cancer (Version 4.2020). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf (2020).

4. Yap, T. A., Banerji, U., de Bono, J. S. & Workman, P. Biopsy-derived biomarkers in phase I trials: building confidence in drug development. J. Clin. Oncol. 34, 2431–2432 (2016).

5. Banerji, U., de Bono, J., Judson, I., Kaye, S. & Workman, P. Biomarkers in early clinical trials: the committed and the skeptics. Clin. Cancer Res. 14, 2512 (2008). author reply 2513–2514.

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3